VivoSeq
Other

Enuresis

24

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Enuresis is an emerging landscape with 24 programs across 11 companies. The most active players are Map77, Neurim Pharmaceuticals Ltd., Vitae Pharmaceuticals Inc., an Allergan affiliate. 6 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Map77

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3Astellas logo

Astellas

2 programs

Phase 3K

Kenvue Brands

1 program

ApprovedFerring logo

Ferring

4 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

26

clinical trials

Completed12 · 46%
Unknown status9 · 35%
Active, not recruiting2 · 8%
Recruiting2 · 8%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

New Treatment for Nocturnal Enuresis in Children
Recruiting·SSohag University·N/A·NCT06497647·450 enrolled
Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis
Recruiting·—·N/A·NCT06285006·50 enrolled
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
Active, not recruiting·MMenoufia University·Phase 3·NCT07398261·151 enrolled
Uroflowmetry and Nocturnal Enuresis
Active, not recruiting·—·N/A·NCT07028645·100 enrolled
Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study
Not yet recruiting·TTanta University·Phase 1·NCT06841666·100 enrolled
Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
Completed·Ferring logoFerring·Phase 3·NCT01078753·89 enrolled
The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal
Completed·UUniversity of Aarhus·Phase 4·NCT00226122·56 enrolled
Ability to Awaken in Nonmonosymptomatic Enuresis
Completed·SSeoul National University Hospital·N/A·NCT02845648·119 enrolled
A New Check-list Method for Nocturnal Enuresis
Completed·—·Phase 4·NCT03510975·75 enrolled
A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
Completed·Ferring logoFerring·Phase 4·NCT00209261·221 enrolled
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
Completed·MMenoufia University·N/A·NCT06771128·398 enrolled
Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.
Completed·MMansoura University Hospital·N/A·NCT04191863·260 enrolled
The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.
Completed·UUniversity of Aarhus·Phase 4·NCT03389412·324 enrolled
A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis
Completed·Ferring logoFerring·Phase 4·NCT00245479·802 enrolled
Efficacy and Safety of Vitamin D Supplementation Combined With Alarm Therapy in Treating Nocturnal Enuresis
Completed·—·N/A·NCT06508333·262 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)